| Tweetovi |
| Dhruv Khullar proslijedio/la je tweet | ||
|
Leora Horwitz
@leorahorwitzmd
|
4. velj |
|
With funding from @RWJF, we found health systems publicly announced $2.5B in investments in social determinants in just last 2 years: largest going to housing at $1.6B and employment $1.1B #SDOH healthaffairs.org/doi/full/10.13…
|
||
|
||
| Dhruv Khullar proslijedio/la je tweet | ||
|
Nisarg Patel
@nxpatel
|
30. sij |
|
In a national drug pricing debate begging for nuance, this work and data visualization is 🔥🔥🔥 twitter.com/DhruvKhullar/s…
|
||
|
|
||
|
Dhruv Khullar
@DhruvKhullar
|
30. sij |
|
Reminded of the beauty of @LisaRosenbaum17's writing when re-reading this @NEJM on diagnostic uncertainty:
"Possibility is not the same as probability, but when you’re bearing the weight of another person’s life, the distinction often feels meaningless."
nejm.org/doi/full/10.10…
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
30. sij |
|
Disheartening findings in new @commonwealthfnd report:
US spends much more on health care than other developed countries, but has the lowest life expectancy, highest suicide rates, and highest rates of avoidable deaths.
commonwealthfund.org/publications/i…
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
30. sij |
|
The central insight is that America's drug market is anything but a traditional free market. Lawmakers have constructed every aspect of the system—and thus have many options, beyond price negotiation, to change the calculus for drug innovation & the costs to patients.
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
30. sij |
|
Finally, the Competitive Period starts when other companies are allowed to introduce products to compete with the innovator drug.
Again, policymakers determine when & how generics can compete—which profoundly influences drug company profits, as patents & exclusivities expire.
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
30. sij |
|
If/when a drug is approved, the Monopoly Period begins. This is where the majority of the reward for successful innovation is earned.
Policymakers can influence incentives by deciding how long and how thoroughly new drugs should be protected from competition.
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
30. sij |
|
In the Innovation Period, drugs are developed & tested. Process is risky but there are many ways to reduce risk & cost without allowing companies to charge exorbitant prices.
Question for policymakers is: What is allowed into the market and how much should it cost to get there?
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
30. sij |
|
We explore the 3 stage journey every drug makes during its life—and how adjusting the rewards & costs for drugmakers during each period can influence the overall reward for innovation.
(The Interactive Graphic lets readers see how each policy influences this reward system.) pic.twitter.com/guF1Vkr9sm
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
30. sij |
|
Excited to share new work @NEJM:
Drug prices are a major concern for Americans. We describe the many levers policymakers have—beyond price negotiation—to reduce the cost burden on patients, while maintaining incentives for the innovation society needs.
nejm.org/doi/full/10.10…
|
||
|
|
||
| Dhruv Khullar proslijedio/la je tweet | ||
|
Peter B. Bach, MD
@peterbachmd
|
29. sij |
|
Just out @NEJM from @DhruvKhullar et al. The structure of rewards (and costs) in pharmaceutical drug development. We introduce the 'reward box' interactive graphic to see how the elements interplay, how specific policies affect it. nejm.org/doi/full/10.10…
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
28. sij |
|
Excited to see this collaboration between @quartethealth & @BlueCrossNC! @RobertAccordino @RahulRajkumar11 twitter.com/quartethealth/…
|
||
|
|
||
| Dhruv Khullar proslijedio/la je tweet | ||
|
Gwen Darien
@Gwen_Darien
|
23. sij |
|
Treating Regret nyti.ms/3axNWzG Excellent article by @DhruvKhullar on the consequences of neglecting regret on everyone and calls on health care providers to recognize the impact of regret on patients and families. /1
|
||
|
|
||
| Dhruv Khullar proslijedio/la je tweet | ||
|
André Picard
@picardonhealth
|
23. sij |
|
Regrets, I've had a few: Despite the pervasiveness of regret, doctors often overlook it, by @DhruvKhullar youtube.com/watch?v=w019Mz… nyti.ms/3axNWzG via @NYThealth
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
22. sij |
|
Regret is a powerful emotion many patients & clinicians experience, but one that often goes unexplored.
In @nytimes, I discuss how we can work through regret—and focus not on what might have been but on what still is.
nyti.ms/3axNWzG
|
||
|
|
||
| Dhruv Khullar proslijedio/la je tweet | ||
|
Atheendar Venkataramani
@atheendar
|
21. sij |
|
New descriptive paper with @sebadaza and Zeke Emanuel in @JAMAInternalMed examining association between county-level social mobility (a measure of economic opportunity) and life expectancy at age 40: jamanetwork.com/journals/jamai… 1/
|
||
|
|
||
| Dhruv Khullar proslijedio/la je tweet | ||
|
Hannah Neprash
@hannahneprash
|
13. sij |
|
Our new @AnnalsofIM paper (w/@JMichaelMcW + @Michael_Chernew): patterns of turnover in the physician workforce likely contribute to provider consolidation. (1/7) annals.org/aim/article-ab…
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
13. sij |
|
Thanks to the entire team who worked so hard to make this seamless video visit service available to patients.
If you, a friend, or a family member want to learn more about treatment options available, please check it out or spread the word.
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
13. sij |
|
Excited to announce a new product @nyphospital: our cancer video concierge service.
In a few clicks, newly-diagnosed breast cancer patients can schedule a free, personalized video visit with our fantastic RNs & learn about onc care available @WeillCornell weillcornell.org/breast-cancer-…
|
||
|
|
||
|
|
Dhruv Khullar
@DhruvKhullar
|
9. sij |
|
Loved Deep Work!
|
||
|
|
||